Healthcare
Fosun revises bid for KKR-backed Gland Pharma
Shanghai Fosun Pharmaceutical has altered the terms of its acquisition of a majority stake in India-based Gland Pharma – a deal that will facilitate an exit for KKR – as part of a long-running battle to win regulatory approval.
Deal focus: Creador writes Indonesia health prescription
With a $45 million investment from Creador, Indonesian hospital chain Medikaloka Hermina is preparing its push to reach the country's underserved middle class
Fund focus: OrbiMed scales up for Fund III
US-based healthcare specialist investor OrbiMed once again raises the bar with the closing of its oversubscribed third Asia fund
Profile: Quadria Capital's Abrar Mir
Following a happenstance job placement in healthcare investment, Abrar Mir developed a passion for the sector’s science and ethics. This underpinned the creation of Asia-focused Quadria Capital
Korea, Singapore launch cross-border healthcare incubator
Singapore investor Golden Equator Capital and Korean research organization C&R Healthcare Global have jointly launched an incubation program that will help Korean healthcare start-ups execute Asian expansions via Singapore.
Australia invests $11m across three biotech start-ups
The Australian government has agreed to invest A$13.3 million ($11 million) into three local healthcare start-ups via it’s Biomedical Translation Fund (BTF).
Sequoia China leads $240m round for WuXi NextCode
WuXi NextCode, a genome sequencing analysis business with ties to China-based contract research organization WuXi PharmaTech, has completed a $240 million extended Series B round of funding led by Sequoia China and featuring Temasek Holdings, Yunfeng...
Creador invests $45m in Indonesia hospital chain
Creador has committed IDR600 billion ($45 million) to Indonesia-based hospital chain Medikaloka Hermina.
OrbiMed closes third Asia healthcare fund at $551m
Healthcare-focused investment firm OrbiMed has closed its third Asian private equity fund with $551 million in commitments.
Eight Roads launches $250m China healthcare fund
Eight Roads Ventures, the proprietary investment arm of Fidelity International, has launched its debut China healthcare fund worth $250 million. All the capital comes from the firm's parent.
CITIC PE, 3SBio agree North America acquisition
CITIC Private Equity and Chinese drug developer 3SBio – which the PE firm took public in Hong Kong two years ago – have agreed to buy the contract development and manufacturing (CDMO) business of Canada’s Therapure Biopharma for $423 million, including...
IDFC invests $12m in Indian eye hospital chain
IDFC Alternatives has invested INR750 million ($11.7 million) in ASG Eye Hospital, an Indian chain of eye care facilities backed by Sequoia Capital.
TPG acquires Taiwan healthcare player
TPG Capital has acquired a controlling stake in Taiwan’s OPC Holding, a contract research organization that offers clinical trial services across a number of medical fields.
Mercury gets go-ahead for New Zealand healthcare deal
Australia-based middle market GP Mercury Capital has won regulatory approval to acquire about 50% of Nirvana Health Group, New Zealand’s largest independent primary healthcare services provider.
KKR to take majority stake in Laser Clinics Australia
KKR has acquired a majority stake in cosmetic treatments business Laser Clinics Australia (LCA) at a valuation of A$650 million ($515 million). The deal facilitates a partial exit for The Growth Fund.
BlueRun, Tencent back Chinese healthcare services platform
BlueRun Ventures and Tencent Holdings have co-led a RMB160 million ($24 million) Series A round of funding for Shuidi, a China-based healthcare services platform that aims to help people pay for medical services.
Goldman, Hillhouse invest $90m in China’s Arrail Dental
Goldman Sachs and Hillhouse Capital have jointly invested $90 million in a Series D round of funding for Arrail Dental, a Chinese dental services provider.
Sequoia, Sofina lead $30m round for India’s MedGenome
Sequoia Capital India and Belgian investor Sofina have led a $30 million Series C round for MedGenome, an India and US-based company focused on molecular biology research and diagnostics.
Accel, IDG in $25m Series B for India's CureFit
Indian health and fitness start-up CureFit has raised a $25 million Series B round from a group of investors including Accel Partners and IDG Ventures.
SDIC leads $65m round for China's CF PharmTech
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million Series D round of funding for CF PharmTech, a Chinese manufacturer of inhalers and nasal sprays.
Alibaba, InnoSpring launch China accelerator
InnoSpring and Alibaba Group have jointly launched an accelerator program in China with a view to helping international start-ups access Chinese markets and ecosystems.
Deal focus: Just delivers on cross-border promise
Lilly Asia Ventures, Arch Ventures and Temasek have backed the expansion of Just Biotherapeutics' China-based manufacturing and research operation
China's VC-backed Zai Lab files for US IPO
Zai Lab, a Chinese drug developer backed by several venture capital investors, has filed for a US IPO. The company has yet to indicate how many shares it plans to sell or at what price.
Qiming leads $21m round for Chinese cancer drug developer
China-based cancer drug developer Antengene Corporation has completed a $21 million Series A round of funding led by Qiming Venture Partners.